Additionally, in the more recent FIRE-4.5 study, it was demonstrated that patients with BRAF V600E mutant tumours may benefit from the treatment with 5-fluorouracil, oxaliplatin, leucovorin and irinotecan (FOLFOXIRI) backbone plus bevacizumab25, whereas in contrast, these patients lacked benefits from cetuximab26,27. Here, BRAF is linked to neoplasm.